Sharif et al. previously reported that aqueous α-GalCer treatment for prevention of disease onset in NOD mice failed to enhance the regulatory activity of splenic CD62L+ T cells, which could not inhibit the activity of diabetogenic T cells in a cotransfer T1D model using NOD-SCID mice, although its administration prevented the onset and recurrence of diabetes in NOD mice [23]. This evidence concerns the gene SELL and diabetes mellitus.